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Abstract 
Background: Cancer stem cells (CSCs), a subpopulation in tumors, are known to cause drug resistance, tumor recur‑
rence and metastasis. Based on the characteristic formation of mammospheres in in vitro conditions, the mammos‑
phere formation assay has become an essential tool for quantifying CSC activity in breast cancer research. However, 
manual counting of mammospheres is a time‑consuming process that is not amenable to high‑throughput screen‑
ing, and there are occasional inaccuracies in the process of determining the mammosphere diameter. In this study, 
we proposed a novel automated counting method of mammosphere using the National Institute of Standards and 
Technology (NIST)’s Integrated Colony Enumerator (NICE) with a screening of protein kinase library.
Methods: Human breast cancer cell line MCF‑7 was used for evaluation of tumor sphere efficiency, migration, and 
phenotype transition. Cell viability was assessed using MTT assay, and CSCs were identified by an analysis of CD44 
expression and ALDEFLUOR assay using flow cytometry. Automated counting of mammosphere using NICE program 
was performed with a comparison to the result of manual counting. After identification of inhibitors to ameliorate 
CSC formation by screening a library of 79 protein kinase inhibitors using automated counting in primary, secondary 
and tertiary mammosphere assay, the effect of selected kinase inhibitors on migration, colony formation and epithe‑
lial‑to‑mesenchymal transition (EMT) of MCF‑7 cells was investigated.
Results: Automated counting of mammosphere using NICE program was an easy and less time‑consuming process 
(<1 min for reading 6‑well plate) which provided a comparable result with manual counting. Inhibition of calcium/
calmodulin‑dependent protein kinase II (CaMKII), Janus kinase‑3 (JAK‑3), and IκB kinase (IKK) were identified to 
decrease the formation of MCF‑7‑derived CSCs in primary, secondary and tertiary mammosphere assay. These protein 
kinase inhibitors alleviated TGF‑β1‑induced migration, colony formation and EMT of MCF‑7 cells.
Conclusions: We have developed a novel automated cell‑based screening method which provided an easy, accurate 
and reproducible way for mammosphere quantification. This study is the first to show the efficacy of an automated 
medium‑throughput mammosphere‑counting method in CSC‑related research with an identification of protein 
kinase inhibitors to ameliorate CSC formation.
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Background
Cancer stem cells (CSCs) are a highly tumorigenic cell 
type, comprising the minority of the tumor population. 
CSCs are generally defined by self-renewal characteristics 
and their ability to differentiate into non-stem cancer cells 
[1]. Another important characteristic of CSCs is the resist-
ance to conventional chemotherapy and radiotherapy, 
which causes a drug-resistance and relapse [2]. Therefore, 
therapeutic approaches to target CSCs emerge as a prom-
ising strategy for anti-cancer treatment. Therefore, the 
important effort in CSC research is the identification and 
quantitation of CSCs in laboratory and clinical settings. In 
addition to cell sorting-based CSC identification method, 
marker-specific tracking of subpopulations of cancer cells 
in competitive tumor models has recently been used to 
further establish in vitro and in vivo evidence for the pres-
ence of CSCs. CSCs have distinct markers allowing for 
their isolation based on the expression of specific proteins, 
which includes CD44, CD133, Oct4, Sox2, Nanog, ALDH-
1, ABCG, and CXCL12 [3]. Currently, the standard meth-
ods for assaying CSC activity are in  vivo transplantation 
and in vitro tumorsphere formation [4].
Manual counting method of tumorspheres in in  vitro 
experiment is time-consuming and requires the discrimi-
nation of spheres >50 μm in diameter by the naked eye, 
which makes this assay sometimes unreliable and difficult 
to reproduce. For accurate quantification of mammos-
pheres, we need reliable, reproducible and convenient 
assay.
Understanding the mechanism of CSC formation has a 
paramount significance since it could help identify target 
genes and/or signaling pathways that are responsible for 
gene activation and determination of tumor microenvi-
ronment. Recent evidence suggests that cells undergoing 
the epithelial-to-mesenchymal transition (EMT) acquire 
stem cell-like characteristics [5], suggesting EMT as a 
potential mechanism of CSC formation.
In this study, we proposed the method of medium-
throughput and automated mammosphere counting 
using publicly available colony counting software, the 
National Institute of Standards and Technology (NIST)’s 
Integrated Colony Enumerator (NICE) [6]. To examine 
the efficacy of the NICE program, we screened a library 
of 79 protein kinase inhibitors and validated the effect 
of CaMKII, JAK-3 and IκB IKK inhibitors on mammos-
phere formation and EMT of breast cancer cells, which 
suggest potential target for treatment of breast cancer via 
modulating the development and growth of CSC.
Methods
Materials
Tissue culture plates including 6- and 24-well ultra-low 
attachment cluster plates were obtained from Nunc 
Labware (Waltham, MA, USA). Protein kinase inhibitor 
library was purchased from Enzo Life Science (Screen-
Well™ Kinase Inhibitor Library, Plymouth Meeting, PA, 
USA). Chemicals were obtained from Sigma-Aldrich Co. 
(St. Louis, MO, USA), unless otherwise stated.
Culture of human breast cancer cells and formation 
of mammospheres
Human breast cancer cells, MCF-7, were obtained from 
the American Type Culture Collection (ATCC; Manassas, 
VA, USA). MCF-7 cells were grown in Dulbecco’s Modi-
fied Essential Medium (DMEM; Hyclone, Logan, UT, 
USA) with 10% fetal bovine serum (FBS; Hyclone), 100 
U/ml penicillin, and 100  μg/ml streptomycin (Hyclone). 
Cells were maintained at 37  °C in a humidified incuba-
tor with 5% CO2. To establish primary mammospheres, 
MCF-7 cells were seeded at a density of 3.5–4 × 104 cells/
well in ultra-low attachment 6-well plates containing 2 ml 
of complete MammoCult™ medium (StemCell Technolo-
gies, Vancouver, BC, Canada) which was supplemented 
with 4 μg/ml heparin, 0.48 μg/ml hydrocortisone, 100 U/
ml penicillin, and 100  μg/ml streptomycin. To establish 
secondary mammosphere, primary mammosphere was 
collected into individual conical tubes by gentle centrifu-
gation at 1000 rpm for 1 min. After removal of superna-
tant, cell pellet was trypsinized with 1X EDTA/Trypsin, 
followed by replating a single cell suspension at a density 
of 4 × 104 cells/well in ultra-low attachment 6-well plates 
containing 2 ml of complete MammoCult™ medium [7]. 
In 5  days, the number and size of the mammosphere 
were assessed compared with control. The same proce-
dure was repeated for tertiary mammospheres [7].
Manual counting of mammospheres
After 7-day culture of MCF-7 cell with complete Mam-
moCult™ medium, mammospheres larger than 50  μm 
in diameter were manually counted under an inverted 
microscope (Carl Zeiss AG, Oberkochen, Germany) 
by two researchers (Choi HS & Kim DA) to reduce the 
counting bias of a single researcher. The number of mam-
mospheres was determined from at least three independ-
ent experiments.
Automated counting of mammospheres
MCF-7 cells were plated at a density of 4  ×  104 cells/
well in ultra-low attachment 6-well plates containing 
complete MammoCult™ medium. After 7-day culture 
of MCF-7 cell with complete MammoCult™ medium, 
8-bit gray scale image of mammospheres was acquired 
by placing the cell culture plate on a scanner (HP Scan-
jetG4050, Hewlett-Packard, Palo Alto, CA, USA). Images 
at high resolution (600 dpi) were loaded using the soft-
ware program NICE, which was downloaded from ftp://
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ftp.nist.gov/pub/physics/mlclarke/NICE [6]. For count-
ing, regions of interest (ROIs) were created by choosing 
the desired number of rows and columns (e.g. 2 × 3 for 
a 6-well plate and 4  ×  6 for a 24-well plate), and indi-
vidual ROIs were defined by moving and resizing the 
provided ROI shapes after selecting the ‘elliptical’ set-
ting of the NICE program. The background signal of the 
images was negated using thresholding algorithms, and 
the selected images were automatically counted. To avoid 
counting immature mammosphere, we set the threshold 
parameters. Raw images were processed by background 
manual setting. We then set parameters using resolu-
tion and value which are set to medium and 200, respec-
tively. The mammosphere formation assay determines 
the mammosphere formation efficiency (MFE, %), which 
corresponds to the number of mammospheres per 100× 
MCF-7 cells. Mammosphere size in primary mammos-
phere assay was measured using the software NIS-Ele-
ments BR 4.4 (Nikon, Tokyo, Japan).
Screening of protein kinase inhibitors using automated 
counting method
The kinase inhibitor library containing 79 compounds 
(Screen-Well™ Kinase Inhibitor Library, Plymouth Meet-
ing, PA, USA) was used to evaluate the inhibitory effect 
on mammosphere formation. In 24  h after an addition 
of MammoCult media to MCF-7 cells, cells were treated 
with each inhibitor at a final concentration of 10  μM. 
Number & size of mammosphere were assessed on day 7 
of mammosphere culture.
Flow cytometric analysis of CD44 and CD24 expression
Expression of CD44 and CD24 was determined by FACS 
analysis in MCF-7 cells. After harvesting and trypsi-
nization of cells using 1X Trypsin/EDTA, one million 
cells were suspended and labeled with FITC-conjugated 
anti-human CD44 and PE-conjugated anti-human CD24 
antibodies (BD Pharmingen, San Diego, CA, USA) and 
incubated at 4 °C for 30 min. Then, the cells were washed 
three times with 1X PBS and analyzed on flow cytometry 
(Accuri C6, BD, San Diego, CA, USA).
ALDEFLUOR assay
CSCs were also identified by ALDEFLUOR assay (Stem-
Cell Technologies) by measuring the activity of alde-
hyde dehydrogenase (ALDH). MCF-7 cells were treated 
with 10 μM of protein kinase inhibitors for 24 h, and the 
proportion of ALDH-positive cells was analyzed with 
ALDEFLUOR assay. Briefly, MCF-7 cells were suspended 
with buffer containing BODIPY-aminoacetaldehyde and 
incubated for 45  min at 37  °C. For each sample, cells 
were incubated with or without diethylaminobenzalde-
hyde (DEAB), an ALDH inhibitor. ALDH-positive and 
negative cells were sorted using the FACSCalibur flow 
cytometer (BD Bioscience).
Cell proliferation and viability assay
Cell proliferation and viability were assessed by CellTi-
ter 96® aqueous one solution cell proliferation assay kit 
(Promega, Madison, WI, USA). MCF-7 cells were grown 
in a 96-well plate in the presence of kinase inhibitors (5, 
10 and 20  μM) with DMEM media with 10% (v/v) FBS 
for 48 h. The optical density was determined at 490 nm 
(Dynex Revelation, Dynex Ltd., Billingshurst, UK). Each 
series of data were determined in triplicate.
Transwell migration assay
Each well of a transwell plate (8.0 μm pore size; Corning 
Costar, Tewksbury, MA, USA) was coated with gelatin 
B (1 μg/ml) and dried at 25 °C for 1 h, and inserted into 
24-well plate which was filled with FGF2 (100  ng/ml)-
containing medium. MCF-7 cells were seeded on each 
upper chamber at a density of 2 × 105 with protein kinase 
inhibitors (10  μM). The plate was incubated at 37  °C in 
5% CO2 for 24 h. Cells were stained with 0.6% hematoxy-
lin and 0.5% eosin (H&E), and the upper surface of the 
filter was carefully wiped with cotton-tipped applicator. 
The number of cells migrating to the lower surface of the 
filter was counted.
Colony formation assay
7 × 104 of MCF-7 cells were plated in each well of 6-well 
plates with 0.3% top agar over a 0.6% agar layer. Protein 
kinase inhibitors were added to the top agar at a concen-
tration of 10 μM. Dishes were incubated for 7 days until 
colonies were large enough to be visualized. Colonies 
were stained with 0.005% crystal violet for 1  h, and the 
number of clones was counted.
Western blotting
Proteins isolated from MCF-7 cell or MCF-7-derived 
mammospheres treated with protein kinase inhibitors 
were separated on 10% SDS-PAGE and transferred to a 
polyvinylidine difluoride membrane (Millipore, Bedford, 
MA, USA). Membranes were blocked in 5% nonfat dry 
milk in PBS-Tween 20 (0.1%, v/v) at room temperature 
for 30  min. The blots were incubated in blocking solu-
tion with primary antibodies at 4  °C overnight. Primary 
antibodies used in this experiment were following: mouse 
anti-cytokeratin-18, (CK18) (Santa Cruz, CA, USA), rab-
bit anti-CD24 (Santa Cruz, CA, USA), mouse anti-β-actin 
(Santa Cruz, CA, USA), mouse anti-N-cadherin (BD 
Bioscience, Bedford, MA, USA), and mouse anti-CD44 
(Cell signaling, Danvers, MA, USA). After washing with 
PBS-Tween 20 (0.1%, v/v), the blots were incubated with 
horseradish peroxidase (HRP)-conjugated secondary 
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antibodies corresponding each primary antibodies and 
enhanced using the chemiluminescence detection (Santa 
Cruz).
Statistical analysis
All data were presented as the mean ±  standard devia-
tion (SD). Data were analyzed using Student’s t test. A p 
value lower than 0.05 was considered statistically signifi-
cant (GraphPad Prism 5 Software, San Diego, CA, USA).
Results
Formation of mammospheres from MCF‑7 cells
An incubation of MCF-7 cells with complete MammoC-
ult™ medium resulted in the formation of spherical mam-
mospheres in 7  days (Fig.  1a). Mammospheres derived 
from MCF-7 cells in suspension culture harbored higher 
CD44 levels compared to adherent MCF-7 cells (Fig. 1a). 
Mean diameter of mammosphere was 134.7  μm (range 
80–230 μm) in 7 days of mammosphere culture (Fig. 1b).
Automated counting of MCF‑7 mammospheres using the 
NICE program
Automated mammosphere counting using NICE pro-
gram was less time-consuming (<1 min for reading 6-well 
plate) compared to manual counting with an easy exclu-
sion of immature mammosphere less than 50 μm. Mam-
mosphere formation efficiency (MFE) of MCF-7 cells 
assessed by automatic and manual counting were com-
parable (1.96 vs. 2.23%, p  >  0.05) (Fig.  1c). To confirm 
whether automated counting assay was on a par with 
manual counting, we examined the effect of metformin 
(5 and 10  mM), an antidiabetic drug known to inhibit 
mammosphere formation [8]. An inhibitory effect of 
metformin on MFE assessed by automated and manual 
counting was comparable (Fig. 1d).
Screening of the effect of protein kinase inhibitors 
on mammosphere formation
In order to find the protein kinase inhibitors possess-
ing CSC-suppressing effect, we screened protein kinase 
library consisting of 79 compounds (Screen-Well™ 
Kinase Inhibitor Library, Plymouth Meeting, PA, USA) 
by automatic counting using NICE program. As a 
result, we identified 11 protein kinase inhibitors with 
MFE by more than 50% inhibition at a final concentra-
tion of 10  µM (Table  1). They were specific for Epider-
mal Growth Factor Receptor Kinase (EGFRK) (C6), PKC 
(D9 and D10), CaMKII (E4 and E5), Myosin Light Chain 
Kinase (MLCK) (E6), Extracellular Regulated Kinase 2 
(ERK2) (F1), Protein Kinase C delta (PKC δ) (F10), JAK-3 
(G4), IκB Kinase (IKK) (G5), and GSK-3β (G10). After 
assessing the cytotoxicity of these inhibitors on MCF-7 
cells, we excluded 4 kinase inhibitors that significantly 
decreased the viability of MCF-7 cells at a concentration 
of 10 μM (Fig. 2). Finally, 7 kinase inhibitors were selected 
as potential suppressors of breast CSC formation, which 
were specific for EGFRK, PKC, CaMKII, MLCK, JAK, 
IKK, and GSK-3β (Fig. 2).
Validation of the inhibitory effects of protein kinase 
inhibitors on mammosphere formation
We further analyzed whether these 7 protein kinase 
inhibitors suppressed the formation of mammospheres 
at a lower concentration (5 μM) by automatic counting. 
Inhibitors specific for CaMKII (E4), JAK-3 (G4), and IKK 
pathway (G5) demonstrated a significant inhibitory effect 
on mammosphere formation by more than 50% (Fig. 3a). 
Furthermore, an inhibitory effect of these protein kinase 
inhibitors (E4, G4, and G5) was observed in second-
ary and tertiary mammosphere assay (Fig. 3b). Not only 
the number, but the size of mammosphere was also 
decreased with co-treatment of CaMKII, JAK3 and IKK 
inhibitors by 29.9, 54.2, 36.9%, respectively.
Effect of CaMKII, JAK‑3, and IKK inhibitors on the 
proportion of ALDH‑positive breast cancer cells 
and CD44high/CD24low‑expressing subpopulation
To further confirm the role of CaMKII, JAK-3, and IKK 
kinase in CSC formation, we investigated the effect of 
these kinase inhibitors on proportion of breast cancer 
cells with ALDH activity and CD44high/CD24low-express-
ing subpopulation in MCF-7 cells. CaMKII, JAK-3, and 
IKK inhibitors decreased the proportion of ALDH-pos-
itive breast cancer cells (Fig.  4a) and CD44high/CD24low 
subpopulation (Fig.  4b). The CD44 expression of MCF-
7-derived mammosphere was higher than MCF-7 cells, 
suggesting the stemness of mammosphere. CaMKII, 
JAK3 and IKK inhibitors decreased CD44 expression 
with an increase in CD24 in mammosphere (Fig. 4c, d).
Effect of CaMKII, JAK‑3, and IKK inhibitors on migration, 
colony formation, and EMT of MCF‑7 cells
The CaMKII, JAK-3, and IKK inhibitors decreased the 
migration and colony formation of MCF-7 cells (Fig. 5a, 
b). In addition, these inhibitors ameliorated the TGF-
β1-induced EMT in MCF-7 cells (Fig. 5c, d). As shown 
in Fig.  5c, TGF-β1 induced a morphologic transition 
of MCF-7 cells including an elongation of cell shape 
with a loss of cell-to-cell contact, which was alleviated 
by CaMKII, JAK-3, and IKK inhibitors. CaMKII, JAK-
3, and IKK inhibitors also reversed TGF-β1-induced 
alteration of the expression of epithelial and mesenchy-
mal cell markers, CK18 and N-cadherin, respectively 
(Fig. 5d, e).
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Fig. 1 Formation of mammospheres from MCF‑7 cells and automated counting of mammospheres using NICE software. a Spheres derived from 
a single cell suspension of MCF‑7 cells are visible in 7 days of culture with complete MammoCult™ medium. CD44 expression in mammospheres 
(gray) assessed by FACS analysis using FITC‑anti‑CD44 is higher compared to adherent MCF‑7 cells (black). b The representative image of tumor 
spheres are shown with diameter of each measured by NIS‑Elements BR4.4 software (Nikon, Tokyo, Japan). c Among mammospheres in the initial 
scanned image (Original), spheres larger than 50 μm in diameter are selected, counted and marked with a red crosshair (Counted) after histogram 
pitting using NICE software. The number of mammospheres counted by NICE software is comparable with the result of manual counting by naked 
eye under an inverted microscope. d Metformin (5 and 10 mM) significantly ameliorates the formation of mammospheres, which is demon‑
strated as a decrease in mammosphere formation efficiency (MFE) quantified by the NICE program and manual counting. The data shown are the 
mean ± SD of 3 independent experiments. *p < 0.05 vs. 0 mM. #p < 0.05 vs. 0 and 5 mM. The scale bar is 100 μm
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Table 1 Summary of protein kinase inhibitors suppressing mammosphere formation
Number Name Targets Inhibitory 
activity
Number Name Targets Inhibitory 
activity
B1 PD‑98059 MEK Negative C1 Tyrphostin 46 EGFRK, PDGFRK Negative
B2 U‑0126 MEK Negative C2 Tyrphostin 47 EGFRK Negative
B3 SB‑203580 p38 MAPK Negative C3 Tyrphostin 51 EGFRK Negative
B4 H‑7 2HCl PKA, PKG, MLCK, 
PKC
Negative C4 Tyrphostin 1 Negative control 
for tyrosine 
kinase
Negative
B5 H‑9 HCl PKA, PKG, MLCK, 
PKC
Negative C5 Tyrphostin AG 1288 Tyrosine kinases Negative
B6 Staurosporine Pan‑specific Negative C6 Tyrphostin AG 1478 EGFRK Positive
B7 AG‑494 EGFRK, PDGFRK Negative C7 Tyrphostin AG1295 Tyrosine kinases Negative
B8 AG‑825 HER1‑2 Negative C8 Tyrphostin 9 PDGFRK Negative
B9 Lavendustin A EGFRK Negative C9 Hydroxy‑2‑naphthalenyl meth‑
ylphosphonic acid
IRK Negative
B10 RG‑1462 EGFRK Negative C10 PKC‑412 PKC inhibitor Negative
B11 Tyrphostin 23 EGFRK Negative C11 Piceatannol Syk negative
B12 Tyrphostin 25 EGFRK Negative C12 PP1 Src family Negative
D1 AG‑490 JAK‑2 Negative E1 HA‑1004 2HCl PKA, PKG Negative
D2 AG‑126 IRAK Negative E2 HA‑1077 2HCl PKA, PKG Negative
D3 AG‑370 PDGFRK Negative E3 2‑Hydroxy‑5‑(2,5‑dihydroxy 
benzyl amino) benzoic acid
EGFRK, CaMK II Negative
D4 AG‑879 NGFRK Negative E4 KN‑62 CaMK II Positive
D5 LY 294002 PI 3‑K Negative E5 KN‑93 CaMK II Positive
D6 Wortmannin PI 3‑K Negative E6 ML‑7 HCl MLCK Positive
D7 GF 109203X PKC Negative E7 ML‑9 HCl MLCK Negative
D8 Hypericin PKC Negative E8 2‑Aminopurine p58 PITSLRE 
beta1
Negative
D9 Ro 31‑8220 
mesylate
PKC Positive E9 N9‑isopropyl‑olomoucine CDK Negative
D10 d‑Erythro‑Sphin‑
gosine
PKC Positive E10 Olomoucine CDK Negative
D11 H‑89 2HCl PKA, Negative E11 Iso‑olomoucine Negative control 
for olomoucine
Negative
D12 H‑8 PKA, PKG Negative E12 Roscovitine CDK Negative
F1 5‑Iodotubericidin ERK2, CK1, CK2 Positive G1 Erbstatin analog EGFRK Negative
F2 LFM‑A13 BTK Negative G2 Quercetin 2H2O PI 3‑K Negative
F3 SB‑202190 p38 MAPK Negative G3 SU1498 Flk1 Negative
F4 PP2 Src family Negative G4 ZM 449829 JAK‑3 Positive
F5 ZM 336372 cRAF Negative G5 BAY 11‑7082 IKK pathway Positive
F6 SU 4312 Flk1 Negative G6 5,6‑dichloro‑1‑β‑d‑
ribofuranosylbenzimidazole
CK II Negative
F7 AG‑1296 PDGFRK Negative G7 2,2′,3,3′,4,4′‑Hexahydroxy‑1,1′‑
biphenyl‑6,6′dimethanol 
dimethyl ether
PKC alpha, PKC 
gamma
Negative
F8 GW 5074 cRAF Negative G8 SP 600125 JNK Negative
F9 Palmitoyl‑dl‑
carnitine
PKC Negative G9 Indirubin GSK‑3beta, CDK5 Negative
F10 Rottlerin PKC delta Positive G10 Indirubin‑3′‑monooxime GSK‑3beta Positive
F11 Genistein Tyrosine kinases Negative G11 Y‑27632 2HCl ROCK Negative
F12 Daidzein Negative control 
for genistein
Negative G12 Kenpaullone GSK‑3beta Negative
H2 Triciribine Akt signaling Negative H6 Apigenin CK‑II Negative
H3 BML‑257 Akt Negative H7 BML‑265 EGFRK Negative
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Table 1 continued
Number Name Targets Inhibitory 
activity
Number Name Targets Inhibitory 
activity
H4 SC‑514 IKK2 Negative H8 Rapamycin mTOR Negative
H5 BML‑259 Cdk5/p25 Negative
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Fig. 2 Effects of protein kinase inhibitors on the viability of MCF‑7 cells. Among 11 protein kinase inhibitors selected based on an inhibitory effect 
on mammosphere formation using the NICE program, the PKC inhibitor (D9), CAMKII inhibitor (E5), ERK 2 inhibitor (F1), and PKC‑δ inhibitor (F10) 
significantly decrease cell viability at 48 h. The data shown represent the mean ± SD of 3 independent experiments. *p < 0.05 vs. each control
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(See figure on previous page.) 
Fig. 3 Effects of protein kinase inhibitors on the mammosphere formation. a EGFRK, PKC, CAMKII, MLCK, JAK‑3, IKK, and GSK‑3β inhibitors signifi‑
cantly decrease the mammosphere‑forming efficiency (MFE) at the concentrations of 5 or 10 μM. In particular, the CAMKII (E4), JAK‑3 (G4), and IKK 
(G5) inhibitors demonstrate >50% inhibition of MFE at 5 μM. b The inhibitory effect of CAMKII (E4), JAK‑3 (G4), and IKK (G5) inhibitors on MFE is also 
observed in secondary and tertiary mammosphere assay. Representative images with quantitation bar are shown (scale bar 100 μm). *p < 0.05 vs. 
each control
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Fig. 4 Effects of protein kinase inhibitors on the expression of ALDH, CD44 and CD24. a ALDH‑positive cells, quantified by the ALDEFLUOR assay, 
are significantly decreased with treatment of CAMKII, JAK‑3, and IKK inhibitors (10 µM) in MCF‑7 cells. The upper panel shows ALDH‑positive cells 
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of CD44/CD24 in MCF‑7‑derived mammosphere (MCF‑7 M) is also demonstrated in western blotting. β‑actin is used as a loading control. Repre‑
sentative western blot analysis with a quantitation bar is shown. The data shown represent the mean ± SD of 3 independent experiments. *p < 0.05 
vs. MCF‑7, #p < 0.05 vs. MCF‑7 M
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Discussion
In this study, we proposed an easy, accurate and less 
time-consuming method of tumor sphere quantitation 
using NICE program for the first time. Using this auto-
matic counting method, we screened the protein kinase 
inhibitor library, and identified 3 protein kinase inhibi-
tors, which had a significant inhibitory effect on forma-
tion of primary, secondary and tertiary mammosphere 
of breast cancer cells. We further confirmed the effect of 
these protein kinase inhibitors targeting CaMKII, JAK-3, 
and IKK on cell migration, colony formation and TGF-β-
induced EMT of MCF-7 cells.
Human solid tumors are phenotypically and function-
ally heterogeneous. Solid tumors contain CSCs that are 
responsible for sustaining tumor growth, which can 
partially account for the functional heterogeneity of solid 
cancer. CSCs have the capacity for self-renewal and gen-
erating tumors resembling the parental tumors, which 
can be a cause of drug resistance or recurrence of can-
cer [3]. In breast cancer, CSCs have been identified as a 
subpopulation of tumor [9, 10]. The recurrence rate of 
breast cancer is approximately 40%, and the recurrence 
is known to be closely linked to patients’ survival. There-
fore, the research on CSCs is one of the most promising 
ways to improve patients’ survival with an understand-
ing of the mechanisms by which CSCs are developed and 
maintained.
The gold standard assay for studying CSCs is xeno-
graft transplantation, however a simple and cost-effec-
tive assay for examining CSC activity is tumorsphere 
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independent experiments. *p < 0.05 vs. control, #p < 0.05 vs. others
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formation assay [11]. The mammosphere formation assay 
in breast cancer is based on the special property of CSCs 
to survive and grow in an anchorage-independent man-
ner, while differentiated cancer cells undergo anoikis or 
die [12]. Although it is challenging to isolate and enrich 
the CSCs from a solid tumor, culturing of stem cells from 
breast cancer tissue or cell lines has been well adapted in 
breast cancer research [10, 13].
In this study, we proposed the method of automated 
mammosphere counting, which allowed for medium-
throughput screening of small molecules or chemicals 
as potential inhibitors of CSCs activity. We confirmed 
the automated counting using the NICE program is reli-
able and more convenient compared to manual count-
ing. The mammosphere counting procedure using the 
NICE program suggested in this study consists of the 
following three steps: (1) acquiring an original image, (2) 
operating the NICE program, and 3) counting the mam-
mospheres which took less than 1 min for reading 6-well 
plate. In general, manual counting is a time-consum-
ing process and discriminating mammospheres larger 
than 50  μm in diameter by naked eyes can be difficult, 
resulting in potentially inaccurate data. The automated 
counting method proposed by this study can overcome 
these limitations of manual counting currently in use. 
Recently, Choudhry P also reported the accuracy and 
reliability of colony counting using several open-source 
digital methods, which demonstrated Cell Colony Edge 
Detection using ImageJ matched the best with manual 
counting with superior results compared to other open-
source methods in speed, accuracy and applicability [14]. 
Although automated counting using NICE program was 
not included in Choudhry P’s analysis with no direct 
comparison data, each method seems to have a unique 
strength and limitation for colony counting in specific 
experimental condition and the researchers have more 
choices for automatic measurement of tumor spheroid.
Conventional anti-cancer drugs with a proven kill-
ing effect on non-tumorigenic cancer cells usually fail to 
effectively eliminate CSCs [15], which is one of the causes 
of tumor recurrence. To identify new anti-cancer drugs 
against CSCs, it is crucial to understand the cellular 
events involved in the development and survival of CSC. 
Targets against CSCs such as surface markers, telomer-
ase, CSC niche proteins, drug transporter proteins, and 
differentiation-related proteins are proposed [16], how-
ever the most robust targets for killing CSCs are proteins 
involved in signaling pathways [16]. To find novel inhibi-
tors of CSC formation, we have screened a protein kinase 
inhibitor library containing 79 chemicals that target the 
following kinases: CaMK, CDK, CKI & II, EGFRK, GSK, 
IKK, insulin receptor, JAK, JNK, MAPK, MEK, MLCK, 
PI3K, PDGFRK, PKA, PKC, RAF, SAPK, Src-family 
kinases, VEGFR and others. Among them, compounds 
specifically inhibiting mammosphere formation without 
affecting the growth of differentiated cancer cells were 
first selected. Finally, we identified 3 compounds that 
effectively inhibited the formation of mammospheres at 
lower concentration. Since Studies have shown that using 
primary spheroid inhibition alone might not necessarily 
identify agents targeting true self-renewing CSCs [7], we 
further validated the effect of the inhibitors of CaMKII, 
JAK-3 and IKK in subsequent passage of primary sphe-
roid-derived cells into secondary and tertiary spheroid 
condition.
KN-62 (E4) is a cell-permeable CaMKII inhibitor. 
KN-62 has been shown to effectively suppress the expres-
sion of HIF-1α in hepatoma cells [17]. ZM 449829 (G4) is 
a selective JAK-3 inhibitor. STAT3, a downstream target 
of JAK-3, is required for the proliferation and self-renewal 
of cancer stem cells [18–21]. BAY 11-7082 (G5), an IKK 
inhibitor, is reported to repress mammosphere formation. 
Inhibitors of NF-κB pathway have previously been shown 
to inhibit breast cancer stem cell-like cells [22]. In addi-
tion, it was reported that BAY 11-7082 induced apoptosis 
and cell cycle arrest in gastric cancer [23].
Our data showed that the selected kinase inhibitors 
which suppressed CSC formation partially alleviated 
EMT of breast cancer cells. The main signaling pathway 
in TGF-β-induced EMT is the Smad pathway [24]. One of 
the major mechanisms of CSC formation is a phenotype 
transition of cancer cells, such as EMT. The process of 
EMT is characterized by the loss of epithelial cell mark-
ers with an overexpression of mesenchymal markers [5, 9, 
25]. The kinase inhibitors evaluated in this study amelio-
rated TGF-β-induced increase in N-cadherin expression 
and inhibited the migration and colony formation abil-
ity of breast cancer cells. Further studies are necessary to 
elucidate the molecular mechanism of anti-CSC effects 
of CaMKII, JAK-3 and IKK inhibitors in breast cancer 
with a validation in animal model of breast cancer.
In conclusion, our study suggests a simple, medium-
throughput, and automated mammosphere-counting 
method as a useful tool for CSC-related research. Fur-
thermore, we used this assay to screen kinase inhibitors 
that suppress the development of breast CSC. We antici-
pate that our methodology can be adopted as a reliable, 
reproducible and easy tool for screening potential com-
pounds targeting CSCs.
Conclusions
We proposed automated mammosphere-counting 
method as a useful tool for CSC-related research with 
a validation of the inhibitory effect of 3 protein kinase 
inhibitors (CaMKII, JAK3, and IKK inhibitors) on CSC 
formation.
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